Masoomeh Saberian
Research Subjects
Masoomeh Saberian has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
Ali Mohebbi
Tehran university of medical sciences, growth and development research center. Iran
1 shared publication- Ali Rabbani
Department of Pediatrics, School of Medicine, Growth and Development Research Center, Children’s Medical Center, Tehran University of Medical Sciences, Tehran, Iran
1 shared publication - Azin Ghamari
Growth and Development Research Center, Tehran University of Medical Sciences, Tehran, Iran
1 shared publication - Fatemeh Nasiri Kenari
Department of Molecular Genetics, Faculty of Biological Science, Tarbiat Modares University, Tehran, Iran, modares.ac.ir
1 shared publication - Majid Sadeghizadeh
Affiliation Department of Genetics, Faculty of Biological Sciences, Tarbiat Modares University, Tehran, Iran
1 shared publication - Maryam Nasri
Razi Herbal Medicines Research Center, Faculty of Medicine, Lorestan University of Medical Sciences, Khorramabad, Iran
1 shared publication
Latest Publications
- Open Access
- 1 January 2025
- Published by Wiley in BioMed Research International
- Vol. 2025 (1)
Restoring Tamoxifen Sensitivity in Breast Cancer: The Role of lncRNA MALAT1 and NanoCurcumin as Modulators of Drug Resistance
Background: Tamoxifen resistance remains a major clinical challenge in estrogen receptor–positive (ER+) breast cancer, contributing to recurrence and poor prognosis. Long noncoding RNAs (lncRNAs), including MALAT1, UCA1, CYTOR, GAS5, and HOTAIR, have emerged as key regulators of endocrine resistance. Curcumin, a polyphenol with anticancer properties, modulates lncRNA expression, and its bioavailable formulation, NanoCurcumin, enhances therapeutic efficacy. This study evaluates the effects of NanoCurcumin in combination with tamoxifen on lncRNA expression and resistance mechanisms in ER+ breast cancer. Methods: Plasma levels of the selected lncRNAs were assessed via qRT‐PCR in luminal breast cancer patients receiving tamoxifen alone or in combination with NanoCurcumin oral soft gels for 6 months. Bioinformatics analysis of MALAT1 expression was performed using the GEO database. In vitro, MALAT1 expression was evaluated in breast cancer (MCF7) and normal breast (MCF10) cell lines via qRT‐PCR. Tamoxifen‐resistant MCF7 cells were generated through prolonged treatment, and the effects of NanoCurcumin on MALAT1 expression were analyzed over 4 months. Results: In clinical samples, NanoCurcumin significantly reduced MALAT1 expression ( p = 0.02) and trended toward decreased UCA1, CYTOR, and HOTAIR while increasing GAS5 expression. Bioinformatics analysis confirmed MALAT1 upregulation in tamoxifen‐resistant cell lines. In vitro, MALAT1 was significantly elevated in MCF7 cells compared to MCF10 and increased over time with tamoxifen treatment alone. NanoCurcumin reversed this trend, sustaining low MALAT1 levels and mitigating resistance. Conclusion: Our findings suggest that NanoCurcumin mitigates tamoxifen resistance by downregulating MALAT1, offering a novel epigenetic strategy to enhance endocrine therapy efficacy. Further studies should explore lncRNA‐targeted interventions to improve treatment outcomes in ER+ breast cancer.
- 1 January 2025
- Published by Wiley in BioMed Research International
- Vol. 2025 (1)
Open AccessRestoring Tamoxifen Sensitivity in Breast Cancer: The Role of lncRNA MALAT1 and NanoCurcumin as Modulators of Drug Resistance
Background: Tamoxifen resistance remains a major clinical challenge in estrogen receptor–positive (ER+) breast cancer, contributing to recurrence and poor prognosis. Long noncoding RNAs (lncRNAs), including MALAT1, UCA1, CYTOR, GAS5, and HOTAIR, have emerged as key regulators of endocrine resistance. Curcumin, a polyphenol with anticancer properties, modulates lncRNA expression, and its bioavailable formulation, NanoCurcumin, enhances therapeutic efficacy. This study evaluates the effects of NanoCurcumin in combination with tamoxifen on lncRNA expression and resistance mechanisms in ER+ breast cancer. Methods: Plasma levels of the selected lncRNAs were assessed via qRT‐PCR in luminal breast cancer patients receiving tamoxifen alone or in combination with NanoCurcumin oral soft gels for 6 months. Bioinformatics analysis of MALAT1 expression was performed using the GEO database. In vitro, MALAT1 expression was evaluated in breast cancer (MCF7) and normal breast (MCF10) cell lines via qRT‐PCR. Tamoxifen‐resistant MCF7 cells were generated through prolonged treatment, and the effects of NanoCurcumin on MALAT1 expression were analyzed over 4 months. Results: In clinical samples, NanoCurcumin significantly reduced MALAT1 expression ( p = 0.02) and trended toward decreased UCA1, CYTOR, and HOTAIR while increasing GAS5 expression. Bioinformatics analysis confirmed MALAT1 upregulation in tamoxifen‐resistant cell lines. In vitro, MALAT1 was significantly elevated in MCF7 cells compared to MCF10 and increased over time with tamoxifen treatment alone. NanoCurcumin reversed this trend, sustaining low MALAT1 levels and mitigating resistance. Conclusion: Our findings suggest that NanoCurcumin mitigates tamoxifen resistance by downregulating MALAT1, offering a novel epigenetic strategy to enhance endocrine therapy efficacy. Further studies should explore lncRNA‐targeted interventions to improve treatment outcomes in ER+ breast cancer.
- 1 January 2020
- Published by Bentham Science Publishers Ltd. in Endocrine, Metabolic & Immune Disorders - Drug Targets
- Vol. 20 (6) , 963-966
Dyspnea and Cough: A Rare Report of the Kimura Disease
BACKGROUND: Known as a rare disease, Kimura disease is a chronic, allergic and inflammatory process. It may overlap other allergic conditions, as well. CASE PRESENTATION: This study is going to present a 36-year-old woman, with cough, dyspnea and bone pain. Other differential diagnoses were excluded during the investigations. The definite diagnosis was made by excisional biopsy and pathological investigations. CONCLUSION: This was a rare medical condition with remarkable diagnostic challenge.
- 1 January 2020
- Published by Bentham Science Publishers Ltd. in Endocrine, Metabolic & Immune Disorders - Drug Targets
- Vol. 20 (6) , 963-966
Dyspnea and Cough: A Rare Report of the Kimura Disease
BACKGROUND: Known as a rare disease, Kimura disease is a chronic, allergic and inflammatory process. It may overlap other allergic conditions, as well. CASE PRESENTATION: This study is going to present a 36-year-old woman, with cough, dyspnea and bone pain. Other differential diagnoses were excluded during the investigations. The definite diagnosis was made by excisional biopsy and pathological investigations. CONCLUSION: This was a rare medical condition with remarkable diagnostic challenge.